Research progress on multimodality treatment for primary tracheal adenoid cystic carcinoma
10.3760/cma.j.cn113030-20200106-00007
- VernacularTitle:气管腺样囊性癌综合治疗研究进展
- Author:
Guofeng QU
1
;
Juntao RAN
Author Information
1. 兰州大学第一医院放疗科 730000
- Keywords:
Tracheal neoplasm/surgery;
Tracheal neoplasm/postoperative radiotherapy;
Research progress
- From:
Chinese Journal of Radiation Oncology
2021;30(8):858-861
- CountryChina
- Language:Chinese
-
Abstract:
Primary tracheal adenoid cystic carcinoma (TACC) is exceedingly rare. Surgical resection is the main treatment for TACC. Whether the operation is radical or not is a key prognostic factor. Postoperative radiotherapy may be suitable to improve the local control rate and long-term survival for patients with positive surgical margin. For unresectable, recurrent and metastatic TACC patients, definitive radiotherapy, chemotherapy and molecular targeted therapies have yielded certain clinical efficacy. The aim of this review is to summarize the research progress on multimodality treatment for TACC.
